ADVFN Logo

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

VAXX Vaxxinity Inc

0.73
0.041 (5.95%)
28 Mar 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Vaxxinity Inc VAXX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.041 5.95% 0.73 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.67 0.67 0.73 0.7175 0.689
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
28/3/202408:23GLOBEVaxxinity to Present Clinical Data at the Annual Academy of..
27/3/202415:41GLOBEVaxxinity Reports Fourth Quarter and Full-Year 2023..
07/3/202409:32GLOBEVaxxinity Announces Positive Target Engagement Data from..
15/2/202415:15EDGAR2Form 8-K - Current report
15/2/202407:00GLOBEVaxxinity’s Cholesterol Vaccine Candidate Successfully..
13/2/202407:00GLOBEVaxxinity to Present Clinical and Preclinical Pipeline Data..
12/2/202416:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202416:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/1/202407:00GLOBEVaxxinity Announces Research Collaboration on Active..
18/1/202407:00GLOBEVaxxinity Announces Collaboration on Space Medicine Research..
03/1/202407:00GLOBEVaxxinity to Present at the 2024 J.P. Morgan Healthcare..
01/12/202309:30EDGAR2Form 8-K - Current report
30/11/202316:03EDGAR2Form 144 - Report of proposed sale of securities
30/11/202315:54EDGAR2Form 144 - Report of proposed sale of securities
29/11/202316:13EDGAR2Form 144 - Report of proposed sale of securities
29/11/202316:10EDGAR2Form 144 - Report of proposed sale of securities
21/11/202315:21EDGAR2Form 144 - Report of proposed sale of securities
21/11/202315:20EDGAR2Form 144 - Report of proposed sale of securities
13/11/202317:50GLOBEVaxxinity to Present at Upcoming November Medical and..
08/11/202307:30GLOBEVaxxinity Reports Third Quarter 2023 Financial Results and..
08/11/202306:53EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202315:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202315:33EDGAR2Form 144 - Report of proposed sale of securities
04/10/202315:24EDGAR2Form 144 - Report of proposed sale of securities
28/9/202315:15EDGAR2Form 8-K - Current report
22/9/202315:16EDGAR2Form 144 - Report of proposed sale of securities
22/9/202315:12EDGAR2Form 144 - Report of proposed sale of securities
29/8/202307:00GLOBEVaxxinity to Present at Upcoming Investor Conferences in..
20/8/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
10/8/202307:00GLOBEVaxxinity Announces Publication of UB-311 Safety,..
09/8/202307:00GLOBEVaxxinity Reports Second Quarter 2023 Financial Results and..
09/8/202306:31EDGAR2Form S-3 - Registration statement under Securities Act of..
09/8/202306:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
27/7/202315:30GLOBEVaxxinity Appoints Peter Powchik, M.D., to Executive Vice..
27/7/202315:04EDGAR2Form 8-K - Current report
17/7/202307:00GLOBEVaxxinity Demonstrates Target Engagement of Toxic..
22/6/202307:00GLOBEVaxxinity Announces UB-312 Successfully Met Primary..
09/5/202307:00GLOBEVaxxinity Reports First Quarter 2023 Financial Results and..

Su Consulta Reciente

Delayed Upgrade Clock